Mural Oncology plc
NasdaqGM MURA
Mural Oncology plc Return on Equity (ROE) for the year ending December 31, 2023
Mural Oncology plc Return on Equity (ROE) is NA for the year ending December 31, 2023. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.
Key data
| Date | Return on Equity (ROE) | Return on Capital Employed (ROCE) | Interest Coverage Ratio | Debt to Equity Ratio |
|---|
Market news
Loading...
NasdaqGM: MURA
| CEO | Ms. Caroline J. Loew Ph.D. |
| IPO Date | Nov. 16, 2023 |
| Location | Ireland |
| Headquarters | 10 Earlsfort Terrace |
| Employees | 107 |
| Sector | Health Care |
| Industries | |
Description
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email